Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases.

Chimeric antigen receptor (CAR) based therapies have been adopted as an option for treating autoimmune diseases from the field of blood malignancies by targeting immune cells or rebalancing the pro-inflammatory milieu. Important questions still remained about the efficacy and safety regarding the dynamic and complex autoimmune pathological networks. We here reviewed the emerged developments in basic, translational, and clinical studies of the CAR based therapies in a wide spectrum of autoimmune diseases. The primary goal of the study is to provide some future perspectives on how to optimize the performance of CAR based therapies. The fundamental strategy is to engineer the recognition domains in CAR products for precisely targeting the components in the pro-inflammatory milieu. The second strategy is to incorporate multiple CARs in one carrier, or use fluorescein isothiocyanate (FITC)-CAR T cells for enhancing the therapeutic efficacy. In addition, we reviewed the preclinical evidence in disease-specific context. Overall, we aim to attract more attention in the field of developing future precision CAR based therapies to tailor medial decisions in autoimmune diseases. • CAR-based therapies eliminate self-reactive lymphocytes and/or rebalance the pro-inflammatory milieu. • Tailored recognition domains is critical for selecting precise targets regarding the heterogeneity of autoimmune disease. • Carrier cell types also play an important role in the performance of CAR-based therapies • Future optimized CAR-based therapies may have a role in precision therapies in treating autoimmune disease. [ABSTRACT FROM AUTHOR]